Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic and Monitoring Significance of Circulating Tumor DNA (ctDNA) Methylation Analysis by Next-Generation Sequencing in Benign and Malignant Pulmonary Nodules

NCT03651986 is registered in ClinicalTrials.gov with AnchorDx Medical Co., Ltd. as lead sponsor.

NCT NCT03651986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03651986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic and Monitoring Significance of Circulating Tumor DNA (ctDNA) Methylation Analysis by Next-Generation Sequencing in Benign and Malignant Pulmonary Nodules
Lead sponsor
AnchorDx Medical Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
November 26, 2018
Completion date
June 30, 2025
Enrollment
10,560 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary nodules